688553 汇宇制药
已收盘 12-31 15:00:01
资讯
新帖
简况
每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书
证券之星 · 2025-12-28
每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书
汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书
智通财经 · 2025-12-23
汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
智通财经 · 2025-12-19
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
汇宇制药:盐酸尼卡地平注射液获得药品注册证书
证券之星 · 2025-12-12
汇宇制药:盐酸尼卡地平注射液获得药品注册证书
汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%
证券之星 · 2025-12-11
汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%
汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金
智通财经 · 2025-11-27
汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金
汇宇制药涨5.37%,开源证券二个月前给出“买入”评级
证券之星 · 2025-11-24
汇宇制药涨5.37%,开源证券二个月前给出“买入”评级
每周股票复盘:汇宇制药(688553)多款产品获境外上市许可
证券之星 · 2025-11-23
每周股票复盘:汇宇制药(688553)多款产品获境外上市许可
汇宇制药(688553.SH):HYP-6589片联合用药获得药物临床试验申请受理
智通财经 · 2025-11-21
汇宇制药(688553.SH):HYP-6589片联合用药获得药物临床试验申请受理
11月21日汇宇制药跌5.99%,创金合信医疗保健股票A基金重仓该股
证券之星 · 2025-11-21
11月21日汇宇制药跌5.99%,创金合信医疗保健股票A基金重仓该股
汇宇制药(688553)披露公司产品获得境外上市许可,11月19日股价下跌5.24%
证券之星 · 2025-11-19
汇宇制药(688553)披露公司产品获得境外上市许可,11月19日股价下跌5.24%
11月19日汇宇制药跌5.24%,创金合信医疗保健股票A基金重仓该股
证券之星 · 2025-11-19
11月19日汇宇制药跌5.24%,创金合信医疗保健股票A基金重仓该股
汇宇制药(688553.SH):多款产品获得境外上市许可
智通财经 · 2025-11-19
汇宇制药(688553.SH):多款产品获得境外上市许可
每周股票复盘:汇宇制药(688553)创新药HY-0005进入I期爬坡试验
证券之星 · 2025-11-16
每周股票复盘:汇宇制药(688553)创新药HY-0005进入I期爬坡试验
汇宇制药(688553)披露依托泊苷注射液获得药品注册证书,11月14日股价下跌0.88%
证券之星 · 2025-11-14
汇宇制药(688553)披露依托泊苷注射液获得药品注册证书,11月14日股价下跌0.88%
汇宇制药(688553.SH):依托泊苷注射液获得药品注册证书
智通财经 · 2025-11-14
汇宇制药(688553.SH):依托泊苷注射液获得药品注册证书
每周股票复盘:汇宇制药(688553)将召开Q3业绩说明会
证券之星 · 2025-11-09
每周股票复盘:汇宇制药(688553)将召开Q3业绩说明会
汇宇制药(688553)披露召开2025年第三季度业绩说明会公告,11月06日股价下跌0.52%
证券之星 · 2025-11-06
汇宇制药(688553)披露召开2025年第三季度业绩说明会公告,11月06日股价下跌0.52%
每周股票复盘:汇宇制药(688553)Q3净利降81.55%
证券之星 · 2025-11-02
每周股票复盘:汇宇制药(688553)Q3净利降81.55%
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
智通财经 · 2025-10-31
汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可
加载更多
公司概况
公司名称:
四川汇宇制药股份有限公司
所属行业:
医药制造业
上市日期:
2021-10-26
主营业务:
四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。
发行价格:
38.87
{"stockData":{"symbol":"688553","market":"SH","secType":"STK","nameCN":"汇宇制药","latestPrice":17.79,"timestamp":1767164401000,"preClose":17.69,"halted":0,"volume":2868062,"delay":0,"changeRate":0.0057,"floatShares":344000000,"shares":424000000,"eps":0.1116,"marketStatus":"已收盘","change":0.1,"latestTime":"12-31 15:00:01","open":17.69,"high":18.11,"low":17.52,"amount":51086700,"amplitude":0.0334,"askPrice":17.79,"askSize":287,"bidPrice":17.77,"bidSize":20,"shortable":0,"etf":0,"ttmEps":0.1116,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":17.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":19.46,"lowLimit":15.92,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423600000,"isCdr":false,"pbRate":2.02,"roa":"--","peRate":159.408602,"roe":"--","epsLYR":0.77,"committee":-0.419549,"marketValue":7536000000,"turnoverRate":0.0083,"status":0,"afterMarket":{"amount":0,"volume":0,"close":17.79,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":17.69},"floatMarketCap":6112000000},"requestUrl":"/m/hq/s/688553","defaultTab":"news","newsList":[{"id":"2594479244","title":"每周股票复盘:汇宇制药(688553)西咪替丁注射液获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594479244","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594479244?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:01","pubTimestamp":1766862074,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,汇宇制药报收于17.88元,较上周的18.64元下跌4.08%。本周关注点公司公告汇总:西咪替丁注射液获得药品注册证书,视同通过仿制药一致性评价。公司公告汇总自愿披露西咪替丁注射液获得药品注册证书的公告四川汇宇制药股份有限公司近日收到国家药品监督管理局核准签发的西咪替丁注射液《药品注册证书》,该产品注册分类为化学药品3类,视同通过仿制药质量和疗效一致性评价。西咪替丁注射液主要用于治疗消化道溃疡。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2593546738","title":"汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593546738","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593546738?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:34","pubTimestamp":1766475255,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的公司产品西咪替丁注射液的《药品注册证书》,西咪替丁注射液主要适应症为消化道溃疡。公司获批的西咪替丁注射液注册分类为化学药品3类,按照与参比制剂质量和疗效一致的技术要求审评并获批,批准后视同通过仿制药质量和疗效一致性评价。根据国家相关政策,通过一致性评价的药品品种在医保支付及医疗机构采购等领域将获得更大的支持力度。公司研发的西咪替丁注射液通过仿制药一致性评价,提升了自身的竞争能力,对公司的发展起到积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"汇宇制药(688553.SH):西咪替丁注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2592159532","title":"汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2592159532","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592159532?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:41","pubTimestamp":1766130101,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司子公司Seacross (Europe) Pharma Ltd.于近期分别收到意大利药品管理局和挪威药品管理局核准签发的公司产品注射用紫杉醇(白蛋白结合型)的上市许可。公司研发的注射用紫杉醇(白蛋白结合型)分别获得意大利、挪威的上市许可,有利于公司在国际市场产品管线的丰富,提升市场的品牌形象,持续拓展国际业务的广度和深度,为国际市场的可持续发展进一步夯实了基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2590831576","title":"汇宇制药:盐酸尼卡地平注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590831576","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590831576?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:43","pubTimestamp":1765525380,"startTime":"0","endTime":"0","summary":"汇宇制药公告称,公司近日收到国家药品监督管理局核准签发的公司产品盐酸尼卡地平注射液的《药品注册证书》。该药品注册分类为化学药品4类,批准后视同通过仿制药质量和疗效一致性评价。盐酸尼卡地平注射液临床上用于手术时异常高血压的紧急处理和高血压急症。根据米内网数据显示,2025年上半年中国城市公立医院终端盐酸尼卡地平注射液销售额约为3.06亿元。产品注册批件的取得在短期内对公司经营业绩不构成重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2590035514","title":"汇宇制药(688553)披露持股5%以上股东股份被轮候冻结的公告,12月11日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590035514","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590035514?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:40","pubTimestamp":1765464026,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘,汇宇制药报收于18.65元,较前一交易日下跌1.17%,最新总市值为79亿元。公司近日发布公告称,截至公告披露日,四川汇宇制药股份有限公司股东黄干益先生持有公司股份27,219,439股,占公司总股本的6.43%。近日,其持有的1,300,000股股份被四川省安岳县人民法院轮候冻结,占其所持股份的4.78%,占公司总股本的0.31%,冻结原因为债务合同纠纷保全。截至2025年12月10日,黄干益累计被轮候冻结股份7,650,738股,占其所持股份的28.11%,占公司总股本的1.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100042420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2586357243","title":"汇宇制药(688553.SH)拟出资1.5亿元参与设立私募基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2586357243","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586357243?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:50","pubTimestamp":1764233428,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司拟与杭州晓池私募基金管理有限公司(简称“晓池资本”)、成都光华梧桐股权投资基金管理有限公司(简称“光华梧桐”)及其他合伙人共同投资设立成都汇宇晓池生物医疗创业投资合伙企业(有限合伙),主要投资于生物医疗领域,重点聚焦管线处于临床关键中后期、具备明确商业潜力的投资标的。该私募基金初始认缴规模为4亿元,公司拟作为有限合伙人以自有资金认缴出资额1.5亿元,占初始总认缴规模出资总额的37.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2585459069","title":"汇宇制药涨5.37%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585459069?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:36","pubTimestamp":1763969800,"startTime":"0","endTime":"0","summary":"今日汇宇制药(688553)涨5.37%,收盘报20.0元。2025年9月3日,开源证券研究员余汝意,刘艺发布了对汇宇制药的研报《公司信息更新报告:扣非净利润稳健增长,创新+出海持续推进》,该研报对汇宇制药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为72.23%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的余汝意、刘艺。汇宇制药(688553)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400013175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","161027"],"gpt_icon":0},{"id":"2585146106","title":"每周股票复盘:汇宇制药(688553)多款产品获境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2585146106","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585146106?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:52","pubTimestamp":1763844730,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘,汇宇制药报收于18.98元,较上周的21.46元下跌11.56%。本周,汇宇制药11月18日盘中最高价报22.11元。公司公告汇总关于自愿披露公司产品获得境外上市许可的公告四川汇宇制药股份有限公司子公司Seacross Pharmaceuticals Ltd.近期获得巴基斯坦、英国和北马其顿药品监管机构核准,其产品普乐沙福注射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液及唑来膦酸注射液取得上市许可。目前国内外尚无同类产品获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2585155681","title":"汇宇制药(688553.SH):HYP-6589片联合用药获得药物临床试验申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2585155681","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585155681?lang=zh_cn&edition=full","pubTime":"2025-11-21 17:00","pubTimestamp":1763715628,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药 发布公告,公司全资子公司四川汇宇海玥医药科技有限公司于2025年11月21日收到国家药品监督管理局核准签发的《受理通知书》,HYP-6589片用于开展与奥希替尼联合治疗靶点驱动基因阳性的晚期非小细胞肺癌的临床试验申请获得受理。HYP-6589片是公司全资子公司汇宇海玥开发的高选择性SOS1小分子抑制剂,其注册分类为化学药1类创新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HYP","BK0239","688553"],"gpt_icon":0},{"id":"2585190862","title":"11月21日汇宇制药跌5.99%,创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190862?lang=zh_cn&edition=full","pubTime":"2025-11-21 15:48","pubTimestamp":1763711315,"startTime":"0","endTime":"0","summary":"证券之星消息,11月21日汇宇制药跌5.99%创60日新低,收盘报18.98元,换手率1.51%,成交量5.2万手,成交额1.01亿元。重仓汇宇制药的前十大公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为创金合信基金的创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.92亿元,最新净值2.1056,较上一交易日上涨0.84%,近一年上涨27.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100018791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2584417947","title":"汇宇制药(688553)披露公司产品获得境外上市许可,11月19日股价下跌5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584417947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584417947?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:36","pubTimestamp":1763562982,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘,汇宇制药报收于20.6元,较前一交易日下跌5.24%,最新总市值为87.26亿元。该股当日开盘21.61元,最高21.88元,最低20.26元,成交额达1.25亿元,换手率为1.75%。近日,汇宇制药发布公告称,公司子公司Seacross Pharmaceuticals Ltd.近期获得巴基斯坦、英国和北马其顿药品监管机构核准,其产品普乐沙福注射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液及唑来膦酸注射液取得上市许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2584915843","title":"11月19日汇宇制药跌5.24%,创金合信医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2584915843","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584915843?lang=zh_cn&edition=full","pubTime":"2025-11-19 15:49","pubTimestamp":1763538553,"startTime":"0","endTime":"0","summary":"证券之星消息,11月19日汇宇制药跌5.24%,收盘报20.6元,换手率1.75%,成交量6.0万手,成交额1.25亿元。重仓汇宇制药的前十大公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为创金合信基金的创金合信医疗保健股票A。创金合信医疗保健股票A目前规模为1.92亿元,最新净值2.1065,较上一交易日下跌0.0%,近一年上涨34.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900021498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2584913794","title":"汇宇制药(688553.SH):多款产品获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2584913794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584913794?lang=zh_cn&edition=full","pubTime":"2025-11-19 15:41","pubTimestamp":1763538096,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司子公司Seacross Pharmaceuticals Ltd.于近期分别收到巴基斯坦药品监督管理局、英国药品和健康产品管理局和北马其顿药品和医疗设备管理局核准签发的公司产品普乐沙福注射液、注射用塞替派、注射用阿扎胞苷、注射用唑来膦酸浓溶液、唑来膦酸注射液的上市许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2583065978","title":"每周股票复盘:汇宇制药(688553)创新药HY-0005进入I期爬坡试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2583065978","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583065978?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:49","pubTimestamp":1763232551,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,汇宇制药报收于21.46元,较上周的20.77元上涨3.32%。本周,汇宇制药11月13日盘中最高价报22.0元。本周关注点来自机构调研要点:创新药HY-0005已获批临床并完成首例受试者给药,目前推进符合预期。公司自主研发的I类创新药HY-0005项目临床试验申请已获批准,并已完成首例受试者入组。截至目前,公司尚未与阿斯利康达成任何药物研究合作,请以公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","688553","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2583502335","title":"汇宇制药(688553)披露依托泊苷注射液获得药品注册证书,11月14日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502335?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:27","pubTimestamp":1763130444,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,汇宇制药报收于21.46元,较前一交易日下跌0.88%,最新总市值为90.9亿元。该股当日开盘21.59元,最高22.0元,最低21.36元,成交额达1.02亿元,换手率为1.36%。公司近日发布公告称,四川汇宇制药股份有限公司近日收到国家药品监督管理局核准签发的依托泊苷注射液《药品注册证书》。依托泊苷注射液适用于小细胞肺癌、恶性淋巴瘤、白血病等多种癌症治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2583760905","title":"汇宇制药(688553.SH):依托泊苷注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583760905","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583760905?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:14","pubTimestamp":1763111662,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药(688553.SH)发布公告,公司于近日收到国家药品监督管理局核准签发的公司产品依托泊苷注射液的《药品注册证书》。依托泊苷注射液主要适应症为小细胞肺癌、恶性淋巴瘤、恶性生殖细胞瘤、白血病,神经母细胞瘤、横纹肌肉瘤、卵巢癌、非小细胞癌,胃癌和食管癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369377.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"汇宇制药(688553.SH):依托泊苷注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0},{"id":"2582643098","title":"每周股票复盘:汇宇制药(688553)将召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582643098","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582643098?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:59","pubTimestamp":1762635548,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,汇宇制药报收于20.77元,较上周的21.85元下跌4.94%。本周,汇宇制药11月3日盘中最高价报22.55元。本周关注点公司公告汇总:汇宇制药将于2025年11月14日召开第三季度业绩说明会。公司公告汇总关于召开2025年第三季度业绩说明会的公告四川汇宇制药股份有限公司将于2025年11月14日上午10:00-11:00通过上证路演中心网络互动平台召开2025年第三季度业绩说明会,就公司2025年第三季度经营成果、财务状况等与投资者进行线上文字互动交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2581052057","title":"汇宇制药(688553)披露召开2025年第三季度业绩说明会公告,11月06日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581052057","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581052057?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:28","pubTimestamp":1762421322,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘,汇宇制药报收于21.07元,较前一交易日下跌0.52%,最新总市值为89.25亿元。公司近日发布公告称,四川汇宇制药股份有限公司将于2025年11月14日上午10:00-11:00通过上证路演中心网络互动平台召开2025年第三季度业绩说明会,就公司2025年第三季度经营成果、财务状况等与投资者进行线上文字互动交流。投资者可于2025年11月7日至11月13日16:00前通过上证路演中心或公司邮箱ir@huiyupharma.com提前提问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600027237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2580476212","title":"每周股票复盘:汇宇制药(688553)Q3净利降81.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580476212","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580476212?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:03","pubTimestamp":1762027393,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,汇宇制药报收于21.85元,较上周的20.95元上涨4.3%。本周,汇宇制药10月31日盘中最高价报22.05元。业绩披露要点2025年前三季度,汇宇制药实现营业收入7.42亿元,同比下降12.92%;归母净利润为-5080.47万元,同比下降122.35%;扣非净利润7956.06万元,同比下降20.62%。第三季度单季营收2.89亿元,同比下降9.7%;归母净利润2991.58万元,同比下降81.55%;扣非净利润3148.74万元,同比下降44.89%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688553"],"gpt_icon":0},{"id":"2579430841","title":"汇宇制药(688553.SH):注射用紫杉醇(白蛋白结合型)获得境外上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2579430841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579430841?lang=zh_cn&edition=full","pubTime":"2025-10-31 15:36","pubTimestamp":1761896209,"startTime":"0","endTime":"0","summary":"智通财经APP讯,汇宇制药 发布公告,公司子公司Seacross Pharma Ltd.和Seacross Pharmaceuticals Ltd.于近期分别收到葡萄牙药品和保健品管理局、英国药品和健康产品管理局核准签发的公司产品注射用紫杉醇的上市许可。公司注射用紫杉醇研发成功后已进行了多国注册申报,目前已在英国、葡萄牙、丹麦、荷兰、爱尔兰、芬兰、瑞典获得上市许可。截至目前,公司已在包含意大利、法国、西班牙等7个国家提交注册申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688553","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767561188025,"stockEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":-0.1047},{"period":"3month","weight":-0.171},{"period":"6month","weight":-0.15},{"period":"1year","weight":0.2015},{"period":"ytd","weight":0.2015}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川汇宇制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13908人(较上一季度减少14.45%)","perCapita":"24700股","listingDate":"2021-10-26","address":"四川省内江市市中区汉阳路333号3幢","registeredCapital":"42360万元","survey":" 四川汇宇制药股份有限公司的主营业务是肿瘤治疗领域创新药和优质仿制药的研发、生产和国内外销售。公司的主要产品是原料药、抗肿瘤注射剂、肿瘤辅助用药等。公司荣登“2022年四川省新经济100强企业榜单”;荣获“四川省2022年度科技创新引才引智先进基地”;荣获“2023年中国医药新锐创新力量”;荣获“四川企业技术创新发展能力100强”且名次跃升至第6位;再次斩获“四川企业技术创新发展最具潜力20强企业”;荣获“2023年度科技人才工作先进单位”表彰授牌。","listedPrice":38.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汇宇制药,688553,汇宇制药股票,汇宇制药股票老虎,汇宇制药股票老虎国际,汇宇制药行情,汇宇制药股票行情,汇宇制药股价,汇宇制药股市,汇宇制药股票价格,汇宇制药股票交易,汇宇制药股票购买,汇宇制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汇宇制药(688553)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汇宇制药(688553)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}